药械

订阅

MedSci主页 / 所有栏目 / 药械

不差钱！Moderna联手阿斯利康推动心血管疾病药物挺进临床研究阶段

2016-07-28 佚名 生物谷

血管疾病药物
关注

英国制药巨头阿斯利康公司和mRNA疗法研发先驱Moderna公司最近宣布双方将进一步推进合作开发的用于治疗心血管疾病的RNA疗法药物AZD8601。Moderna公司一直专注于mRNA药物研发领域，此前公司已经获得了高达12亿美元的风险投资。 Moderna公司目前有两项药物处于临床研究阶段：mRNA1440在欧洲进行以安全性评价为主的临床I期研究，mRNA1851在美国进行临床I期研究。Mo

英国制药巨头阿斯利康公司和mRNA疗法研发先驱Moderna公司最近宣布双方将进一步推进合作开发的用于治疗心血管疾病的RNA疗法药物AZD8601。Moderna公司一直专注于mRNA药物研发领域，此前公司已经获得了高达12亿美元的风险投资。

Moderna公司目前有两项药物处于临床研究阶段：mRNA1440在欧洲进行以安全性评价为主的临床I期研究，mRNA1851在美国进行临床I期研究。Moderna公司并未透露这两种药物设计的具体靶点，仅表示它们都是传染病疫苗类型的药物。目前公司共招募了超过200名健康志愿者参与这两项临床研究。

如今，Moderna公司调整其发展方向，进一步加强了与大型医药巨头的联系。2013年公司与阿斯利康公司签订了合作协议，共同开发AZD8601。研究人员希望通过这种药物刺激一种名为血管内皮生长因子A（VEGF-A），从而达到治疗心脏病的效果。前期研究显示这种生长因子与心脏病、糖尿病创伤恢复以及多种血管疾病有关。Moderna公司表示，公司和阿斯利康将联合Paul Ehrlich Institute和德国联邦卫生部共同开展临床I期研究。

除此之外，双方还将就mRNA疗法在肿瘤免疫疗法领域中展开合作。今年一月份，双方就阿斯利康公司的PD-L1检验点药物durvalumab和mRNA疗法联合达成合作。

事实上，如今的Moderna公司在肿瘤疗法领域可以称得上是炙手可热。默沙东、Alexion等重量级选手纷纷和Moderna公司签订合作协议。

近年来，mRNA疗法的发展遭遇了重重坎坷。Moderna公司能否引领整个mRNA疗法领域，尚待时间的验证。

原始出处：

Cash-rich Moderna to begin first AstraZeneca trial under collab deal

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2008725, encodeId=78fc2008e259b, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri May 19 01:50:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801283, encodeId=d88418012834e, content=<a href='/topic/show?id=df21e345412' target=_blank style='color:#2F92EE;'>#研究阶段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73454, encryptionId=df21e345412, topicName=研究阶段)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd34186, createdName=wshxjq, createdTime=Wed Feb 22 18:50:00 CST 2017, time=2017-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=130890, encodeId=c161130890e4, content=好文，从这里学习了好多新知识，新信息。赞了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Sep 19 16:00:00 CST 2016, time=2016-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498033, encodeId=25181498033c2, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sat Jul 30 10:50:00 CST 2016, time=2016-07-30, status=1, ipAttribution=)]
    2017-05-19 般若傻瓜

    #eRNA#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2008725, encodeId=78fc2008e259b, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri May 19 01:50:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801283, encodeId=d88418012834e, content=<a href='/topic/show?id=df21e345412' target=_blank style='color:#2F92EE;'>#研究阶段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73454, encryptionId=df21e345412, topicName=研究阶段)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd34186, createdName=wshxjq, createdTime=Wed Feb 22 18:50:00 CST 2017, time=2017-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=130890, encodeId=c161130890e4, content=好文，从这里学习了好多新知识，新信息。赞了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Sep 19 16:00:00 CST 2016, time=2016-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498033, encodeId=25181498033c2, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sat Jul 30 10:50:00 CST 2016, time=2016-07-30, status=1, ipAttribution=)]
    2017-02-22 wshxjq

    #研究阶段#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2008725, encodeId=78fc2008e259b, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri May 19 01:50:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801283, encodeId=d88418012834e, content=<a href='/topic/show?id=df21e345412' target=_blank style='color:#2F92EE;'>#研究阶段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73454, encryptionId=df21e345412, topicName=研究阶段)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd34186, createdName=wshxjq, createdTime=Wed Feb 22 18:50:00 CST 2017, time=2017-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=130890, encodeId=c161130890e4, content=好文，从这里学习了好多新知识，新信息。赞了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Sep 19 16:00:00 CST 2016, time=2016-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498033, encodeId=25181498033c2, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sat Jul 30 10:50:00 CST 2016, time=2016-07-30, status=1, ipAttribution=)]
    2016-09-19 ylzr123

    好文，从这里学习了好多新知识，新信息。赞了！

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2008725, encodeId=78fc2008e259b, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri May 19 01:50:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801283, encodeId=d88418012834e, content=<a href='/topic/show?id=df21e345412' target=_blank style='color:#2F92EE;'>#研究阶段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73454, encryptionId=df21e345412, topicName=研究阶段)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd34186, createdName=wshxjq, createdTime=Wed Feb 22 18:50:00 CST 2017, time=2017-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=130890, encodeId=c161130890e4, content=好文，从这里学习了好多新知识，新信息。赞了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Sep 19 16:00:00 CST 2016, time=2016-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498033, encodeId=25181498033c2, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sat Jul 30 10:50:00 CST 2016, time=2016-07-30, status=1, ipAttribution=)]
    2016-07-30 andy2090

    #血管疾病#

    0